This effect is well described for the treatment of BRAF(V600E) mutated melanoma, and combination therapy of BRAF inhibitors and MEK inhibitors has become the standard of care as it is superior to monotherapy [46,47,48]. The gene discussed is MAP2K7; the disease is melanoma.